4, 2014 /PRNewswire/ — SELLAS Life Sciences Group , a Swiss-based development-stage biopharmaceutical company today announced that it has signed an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center for the development, marketing, and commercialization of MSK’s proprietary WT1 cancer vaccine. “This collaboration underscores SELLAS’ commitment to innovative therapies for major unmet medical needs and is of paramount importance and a significant milestone for us,” said , MD, SELLAS Chairman and Chief Executive Officer.
